Previous close | 18.85 |
Open | N/A |
Bid | 0.00 |
Ask | 4.40 |
Strike | 1,007.50 |
Expiry date | 2024-06-28 |
Day's range | 18.85 - 18.85 |
Contract range | N/A |
Volume | |
Open interest | 1 |
TARRYTOWN, N.Y., June 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2024 financial and operating results on Thursday, August 1, 2024, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Call Information Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s webs
Majority of patients in this age group with eosinophilic esophagitis (EoE) receiving Dupixent achieved histologic remission, with improvements sustained up to one year Dupixent is the first and only treatment indicated for EoE in the U.S. for this age group TARRYTOWN, N.Y. and PARIS, June 26, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced the New England Journal of Medicine (NEJM) has published results from a positive Phase 3 trial for Dupixent
Key Insights The projected fair value for Regeneron Pharmaceuticals is US$1,936 based on 2 Stage Free Cash Flow to...